Biotek-snakken — December 2025
-
Servicemeddelelse: Q&A med Adam Steensberg fra Zealand Pharma starter kl. 14.
-
Curasight - Nu bliver det spændende...: Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT[
] in Brain Cancer https://news.cision.com/curasight/r/curasight-announces-successful-d
osing-of-first-patient-in-phase-1-trial-with-utreat--in-brain-cancer,c4284416 -
-
Darvin: FPD var vel ventet af de fleste her inden udgangen af '25 (som Curasight også mere eller mindre havde lovet.,
så tror ikke på et voldsomt hop i morgen. Data til gengæld, der nok kan forventes i starten af næste uge...er de gode / over forventning; så står den måske på en ekstra julegave i år. -
Stockholm, December 19, 2025 – Vicore Pharma Holding AB (publ) (STO: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs) today announced that Nasdaq has completed its annual review of its Nordic market capitalization (market cap) segments and will move Vicore Pharma from the Small Cap segment to the Mid Cap segment effective January 2, 2026.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind